Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
EVP R&D Dr. Fady I. Malik reported one option exercise and a matching open-market sale on 22 Jul 2025. He exercised 2,000 non-qualified options at $10.60, receiving 2,000 CYTK shares (Code M), then sold the same 2,000 shares at $37.47 (Code S). Net share count declined slightly from 142,610 to 140,610 shares, all held directly. Malik still holds 13,105 unexercised options with a $10.60 strike expiring 28 Feb 2027.
The trade represents roughly 1.4% of his direct equity position and appears to be a routine liquidity event following option exercise rather than a wholesale reduction. No other executives are involved and there are no disclosures affecting company fundamentals.